Increased intracardiac vascular endothelial growth factor levels in patients with paroxysmal, but not persistent atrial fibrillation

Europace

Volumn 14, Issue 7, 2012, Pages 948-953

  Scridon, Alina ^a   Morel, Elodie ^b   Nonin Babary, Emilie ^b   Girerd, Nicolas ^b   Fernandez, Carmen ^c   Chevalier, Philippe ^b  

^a UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b LOUIS PRADEL HOSPITAL   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Atrial fibrillation; Inflammation; Vascular endothelial growth factor

Indexed keywords

C REACTIVE PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY SINUS; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PAROXYSMAL HEART ATRIUM FIBRILLATION; PRIORITY JOURNAL; PULMONARY VEIN; WOLFF PARKINSON WHITE SYNDROME;

AGED; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; CHRONIC DISEASE; CYTOKINES; FEMALE; HUMANS; MALE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOLFF-PARKINSON-WHITE SYNDROME;

EID: 84862976645     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eur418     Document Type: Article

References (33)

1. Conway DS, Buggins P, Hughes E, Lip GY. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 2004;43:2075-82.
2. Van Wagoner DR. Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target. J Cardiovasc Pharmacol 2008; 52:306-13.
3. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006;27:136-49.
4. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96:1180-4.
5. Ommen S, Odell J, Stanton M. Atrial arrhythmias after cardiothoracic surgery. N Engl J Med 1997;336:1429-34.
6. Cosgrave J, Foley JB, Kelly R, McGovern E, Bennett K, Young V et al. Perioperative serum inflammatory response and the development of atrial fibrillation after coronary artery bypass surgery. Heart 2005;91:1475-6.
7. Aviles R, Martin D, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003;108:3006-10.
8. Luan Y, Guo Y, Li S, Yu B, Zhu S, Li S et al. Interleukin-18 among atrial fibrillation patients in the absence of structural heart disease. Europace 2010;12:1713-8.
9. Liuba I, Ahlmroth H, Jonasson L, Englund A, Jönsson A, Säfström K et al. Source of inflammatory markers in patients with atrial fibrillation. Europace 2008;10: 848-53.
10. Ellinor PT, Low A, Patton KK, Shea MA, MacRae CA. C-reactive protein in lone atrial fibrillation. Am J Cardiol 2006;97:1346-50.
11. Masson S, Aleksova A, Favero C, Staszewsky L, Bernardinangeli M, Belvito C et al. Predicting atrial fibrillation recurrence with circulating inflammatory markers in patients in sinus rhythm at high risk for atrial fibrillation: data from the GISSI atrial fibrillation trial. Heart 2010;96:1909-14.
12. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation. The task for the management of atrial fibrillation of the European Society of Cardiology (ESC). Europace 2010;12: 1360-420.
13. Korantzopoulos P, Kolettis TM, Kountouris E, Dimitroula V, Karanikis P, Pappa E et al. Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation. Int J Cardiol 2005;102:321-6.
14. Liu T, Li G. Probucol and succinobucol in atrial fibrillation: pros and cons. Int J Cardiol 2010;144:295-6.
15. Watson T, Arya A, Sulke N, Lip GYH. Relationship of indices of inflammation and thrombogenesis to arrhythmia burden in paroxysmal atrial fibrillation. Chest 2010; 137:869-76.
16. Levy AP, Levy NS, Loscalzo J, Calderone A, Takahashi N, Yeo KT et al. Regulation of vascular endothelial growth factor in cardiac myocytes. Circ Res 1995;76: 758-66.
17. Seko Y, Seko Y, Takahashi N, Shibuya M, Yazaki Y. Pulsatile stretch stimulates vascular endothelial growth factor (VEGF) secretion by cultured rat cardiac myocytes. Biochem Biophys Res Commun 1999;254:462-5.
18. Ogi H, Nakano Y, Niida S, Dote K, Hirai Y, Suenari K et al. Is structural remodeling of fibrillated atria the consequence of tissue hypoxia? Circ J 2010;74:1815-21.
19. Li J, Hampton T, Morgan JP, Simons M. Stretch-induced VEGF expression in the heart. J Clin Invest 1997;100:18-24.
20. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite PA. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med 2000;342:626-33.
21. Lee KW, Lip GY, Blann AD. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 2004;110:2355-60.
22. Wong AK, Marais HJ, Jutzy K, Capestany GA, Marais GE. Isolated atrial infarction in a patient with single vessel disease of the sinus node artery. Chest 1991;100: 255-6.
23. Thijssen VL, van der Velden HM, van Ankeren EP, Ausma J, Allessie MA, Borgers M et al. Analysis of altered gene expression during sustained atrial fibrillation in the goat. Cardiovasc Res 2002;54:427-37.
24. Katoh O, Tauchi H, Kawaishi K, Kimura A, Satow Y. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in haemopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res 1995;55:5687-92.
25. Freeman MR, Scheck FX, Gagnon ML, Corless C, Soker S, Niknejad K. Peripheral blood T-lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 1995;55:4140-5.
26. Gaudry M, Bregerie O, Andrieu V, El-Benna J, Pocidalo MA, Hakim J. Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood 1997;90: 4153-61.
27. Chaudhary NI, Roth GJ, Hilberg F, Müller-Quernheim J, Prasse A, Zissel G et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 2007; 29:976-85.
28. Hamada N, Kuwano K, Yamada M, Hagimoto N, Hiasa K, Egashira K et al. Antivascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. J Immunol 2005;175:1224-31.
29. Kallergis EM, Manios EG, Kanoupakis EM, Mavrakis HE, Arfanakis DA, Maliaraki NE et al. Extracellular matrix alterations in patients with paroxysmal and persistent atrial fibrillation: biochemical assessment of collagen type-I turnover. J Am Coll Cardiol 2008;52:211-5.
30. Gramley F, Lorenzena J, Koellensperger E, Kettering K, Weiss C, Munzel T. Atrial fibrosis and atrial fibrillation: the role of the TGF-b1 signaling pathway. Int J Cardiol 2010;143:405-13.
31. Seko Y, Nishimura H, Takahashi N, Ashida T, Nagai R. Serum levels of vascular endothelial growth factor and transforming growth factor-beta1 in patients with atrial fibrillation undergoing defibrillation therapy. Jpn Heart J 2000;41: 27-32.
32. Everett AD, Tufro-McReddie A, Fisher A, Gomez RA. Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1expression. Hypertension 1994;23:587-92.
33. Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller GA, Rangell L et al. VEGF is required for growth and survival in neonatal mice. Development 1999;126: 1149-59.